MedTrace Logo

REQUIP RLS Post Marketing Surveillance

NCT01327339 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 755

Last updated 2017-09-12

Study results available
· View outcomes & findings →

Summary

post-marketing surveillance to monitor safety and efficacy of ropinirole during using of treatment for RLS

Conditions

  • Restless Legs Syndrome

Interventions

DRUG

Ropinirole

Basically there is no treatment allocation. Subjects who would be administered of ropinirole at their physician's direction will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-04-01
Primary Completion
2009-11-30
Completion
2009-11-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01327339 on ClinicalTrials.gov